CO6390114A2 - Anticuerpos anti cxcr4 para el tratamiento - Google Patents

Anticuerpos anti cxcr4 para el tratamiento

Info

Publication number
CO6390114A2
CO6390114A2 CO11162444A CO11162444A CO6390114A2 CO 6390114 A2 CO6390114 A2 CO 6390114A2 CO 11162444 A CO11162444 A CO 11162444A CO 11162444 A CO11162444 A CO 11162444A CO 6390114 A2 CO6390114 A2 CO 6390114A2
Authority
CO
Colombia
Prior art keywords
antibodies
treatment
cxcr4
relates
present
Prior art date
Application number
CO11162444A
Other languages
English (en)
Inventor
Christine Klinguer-Hamour
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41060014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6390114(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of CO6390114A2 publication Critical patent/CO6390114A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se relaciona con anticuerpos aislados novedosos, o los compuestos derivados a los fragmentos funcionales de los mismos, capaces de unirse a CXCR4 pero también para inducir el cambio conformacional de los homodímeros CXCR4 y capaces de inhibir la replicación aislada principal del VIH-1 en PBMC. Más particularmente, la presente invención se relaciona con los anticuerpos monoclonales 515H7 y 301aE5, específicos para la proteína CXCR4, así como también su uso para el tratamiento de infección por VIH. También se cubren composiciones farmacéuticas compuestas de tales anticuerpos y un proceso para la selección de tales anticuerpos.
CO11162444A 2009-04-29 2011-11-25 Anticuerpos anti cxcr4 para el tratamiento CO6390114A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17368009P 2009-04-29 2009-04-29
EP09159076A EP2246364A1 (en) 2009-04-29 2009-04-29 Anti CXCR4 antibodies for the treatment of HIV

Publications (1)

Publication Number Publication Date
CO6390114A2 true CO6390114A2 (es) 2012-02-29

Family

ID=41060014

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11162444A CO6390114A2 (es) 2009-04-29 2011-11-25 Anticuerpos anti cxcr4 para el tratamiento

Country Status (26)

Country Link
US (3) US9090686B2 (es)
EP (2) EP2246364A1 (es)
JP (1) JP5800802B2 (es)
KR (1) KR20120039525A (es)
CN (1) CN102459343B (es)
AU (1) AU2010243526B2 (es)
BR (2) BRPI1011540A2 (es)
CA (1) CA2759989A1 (es)
CL (1) CL2011002664A1 (es)
CO (1) CO6390114A2 (es)
ES (1) ES2534313T3 (es)
GE (1) GEP20146181B (es)
HK (1) HK1165813A1 (es)
HU (1) HUE025083T2 (es)
IL (1) IL215919A0 (es)
MA (1) MA33285B1 (es)
MX (1) MX2011011285A (es)
MY (1) MY155400A (es)
NZ (1) NZ596712A (es)
PL (1) PL2424897T3 (es)
RU (1) RU2573902C2 (es)
SG (1) SG175353A1 (es)
TN (1) TN2011000534A1 (es)
UA (1) UA107929C2 (es)
WO (1) WO2010125162A1 (es)
ZA (1) ZA201108330B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
AU2011322508A1 (en) * 2010-10-27 2013-05-02 Pierre Fabre Medicament Antibodies for the treatment of HIV
US9217040B2 (en) 2011-01-14 2015-12-22 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
AR087363A1 (es) * 2011-07-29 2014-03-19 Pf Medicament Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
US9587012B2 (en) 2013-12-02 2017-03-07 Aaron Diamond Aids Research Center Bispecific HIV-1 neutralizing antibodies
NZ743713A (en) 2015-12-15 2020-01-31 Gilead Sciences Inc Human immunodeficiency virus neutralizing antibodies
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
TWI728250B (zh) 2017-06-21 2021-05-21 美商基利科學股份有限公司 靶向hiv gp120及cd3之多特異性抗體
US11180575B2 (en) 2018-12-28 2021-11-23 Corn Products Development, Inc. Thermally inhibited starch and process for making
CN111918873A (zh) 2018-03-27 2020-11-10 百时美施贵宝公司 使用紫外线信号实时监测滴度
CN111214650A (zh) * 2018-11-23 2020-06-02 广州溯原生物科技有限公司 一种hiv抗原-受体三聚体复合物的解离因子的应用
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
WO2020237221A1 (en) 2019-05-23 2020-11-26 Bristol-Myers Squibb Company Methods of monitoring cell culture media
CA3167936A1 (en) * 2020-01-16 2021-07-22 Cohava Gelber Humanized antibodies specific for myeloma and ovarian cancer cells
JP2023544410A (ja) 2020-10-05 2023-10-23 ブリストル－マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins
US12006353B2 (en) * 2022-07-25 2024-06-11 Long Chen Application of SCFV protein, car gene expression vector, CAR-T cell and application thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US5871732A (en) * 1990-11-27 1999-02-16 Biogen, Inc. Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69334287D1 (de) * 1992-09-25 2009-07-09 Avipep Pty Ltd Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist
EP0854918A1 (en) * 1996-01-30 1998-07-29 The National Institutes of Health Cells expressing both human cd4 and cxcr4
WO2001042308A2 (en) * 1999-12-08 2001-06-14 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US20040093621A1 (en) * 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
MXPA06000252A (es) * 2003-06-30 2006-12-15 Bio Technology General Israel Anticuerpos y usos de los mismos.
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
KR20090052358A (ko) * 2006-09-29 2009-05-25 에프. 호프만-라 로슈 아게 Ｃｃｒ5 에 대한 항체 및 이의 용도
JP5374360B2 (ja) * 2007-02-27 2013-12-25 中外製薬株式会社 抗ｇｒｐ７８抗体を有効成分として含む医薬組成物
JP2011520885A (ja) * 2008-05-14 2011-07-21 イーライ リリー アンド カンパニー 抗ｃｘｃｒ４抗体
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
WO2011059684A1 (en) * 2009-10-29 2011-05-19 Centocor Ortho Biotech Inc. Antibody glycosylation variants
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer

Also Published As

Publication number Publication date
CL2011002664A1 (es) 2012-12-14
MX2011011285A (es) 2012-01-20
PL2424897T3 (pl) 2015-07-31
KR20120039525A (ko) 2012-04-25
EP2246364A1 (en) 2010-11-03
UA107929C2 (en) 2015-03-10
RU2011148077A (ru) 2013-06-10
ZA201108330B (en) 2012-09-26
US20160031995A1 (en) 2016-02-04
BRPI1011540A2 (pt) 2019-04-30
JP2012525129A (ja) 2012-10-22
MY155400A (en) 2015-10-15
IL215919A0 (en) 2011-12-29
ES2534313T3 (es) 2015-04-21
CA2759989A1 (en) 2010-11-04
AU2010243526B2 (en) 2015-02-12
WO2010125162A1 (en) 2010-11-04
HK1165813A1 (en) 2012-10-12
JP5800802B2 (ja) 2015-10-28
AU2010243526A1 (en) 2011-12-22
US20130174288A1 (en) 2013-07-04
SG175353A1 (en) 2011-11-28
US20110088104A1 (en) 2011-04-14
MA33285B1 (fr) 2012-05-02
CN102459343B (zh) 2015-09-16
TN2011000534A1 (en) 2013-05-24
NZ596712A (en) 2013-10-25
GEP20146181B (en) 2014-10-27
RU2573902C2 (ru) 2016-01-27
BR112013009984A2 (pt) 2017-07-18
EP2424897B1 (en) 2015-01-07
HUE025083T2 (en) 2016-02-29
EP2424897A1 (en) 2012-03-07
US9090686B2 (en) 2015-07-28
CN102459343A (zh) 2012-05-16

Similar Documents

Publication Publication Date Title
CO6390114A2 (es) Anticuerpos anti cxcr4 para el tratamiento
CO6571881A2 (es) Nuevos anticuerpos anti-cxcr4 humanizados para el tratamiento del cáncer
GT201200258A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
CR20110509A (es) Composicion farmaceutica
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
UY30573A1 (es) N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2
ECSP14013325A (es) Piridopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr)
UY34116A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
GT200900231A (es) Moduladores 2-aminopirimidina del receptor de histamina h4
CL2009000860A1 (es) Compuestos derivados de 4-fenil-4-metil-5,6-dihidro-4h-1,3-tiazina-2-amina; composiciones farmaceuticas que los contienen; y uso de los compuestos en la preparacion de medicamentos inhibidores de bace, utiles para el tratamiento de trastornos mediados por esta enzima, tal como la enfermedad de alzheimer.
CR20130016A (es) ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
BRPI0909040B8 (pt) derivados de azetidina e ciclobutano, seus usos, e composição
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
GT201100023A (es) Anticuerpos neutralizantes del virus anti - influenza a y usos de los mismos
CL2012002782A1 (es) Compuestos derivados de pirazol-4-il-heterociclil-carboxamida, inhibidores de los trastornos mediados por las quinasas pim-1, pim-2 y pim-3; composición farmacéutica; mètodo de tratamiento; y su uso para el tratamiento del càncer, trastornos inmunes, enfermedades cardiovasculares e infecciones virales , entre otros.
PA8784001A1 (es) Oxazolidinonas sustituidas y su uso
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
CR11196A (es) Compuestos quimicos
CO6541545A2 (es) Compuestos de espiropiperidina como antagonistas del receptor orl-1
UY32574A (es) Antagonistas del receptor cxcr3
DOP2012000250A (es) COMPUESTOS DEL COMPLEJO DE Fe(III) PARA EL TRATAMIENTO Y PROFILAXIS DE LOS SÍNTOMAS DE DEFICIENCIA DE HIERRO Y LAS ANEMIAS POR DEFICIENCIA DE HIERRO
CO6640284A2 (es) Miembros enlazadores para citomegalovirus humano

Legal Events

Date Code Title Description
FG Application granted